ImageneBio, Inc.
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
IMA$3.81-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Nine Months EndedSeptember 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(38,441) | $(31,756) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 6 | 1,119 |
| Non-cash interest expense | 489 | — |
| Stock-based compensation expense | 15,340 | — |
| Accretion/amortization of premium/discount of available-for-sale securities | (33) | — |
| Amortization of right of use-assets | 466 | 313 |
| Gain on early extinguishment of lease liability | (149) | — |
| Loss on disposal of property and equipment | — | 1,287 |
| Non-cash research and development expenses for the common stock issuable pursuant to Hutchmed Agreement | — | 13,965 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (3,574) | (233) |
| Other non-current assets | (1,277) | 121 |
| Accounts payable | (2,179) | (2,236) |
| Accrued expenses and other current liabilities | (9,945) | (731) |
| Deferred revenue | (650) | 650 |
| Operating lease liabilities | (694) | (343) |
| Other long-term liabilities | 15 | - |
| Net cash used in operating activities | $(40,626) | $(17,844) |
| Cash flows from investing activities: | ||
| Cash divested in Non-OX40 divestiture | (5,215) | — |
| Proceeds from disposal of property and equipment | — | 869 |
| Purchases of marketable securities | (1,485) | — |
| Maturities and sales of marketable securities | 2,250 | 10,151 |
| Net cash provided by investing activities | $(4,450) | $11,020 |
| Cash flows from financing activities: | ||
| Proceeds from term loan | 15,000 | — |
| Proceeds from exercise of stock options | 45 | — |
| Issuance costs in connection with reverse recapitalization | (5,338) | — |
| Cash acquired in connection with reverse recapitalization | 54,631 | — |
| Proceeds from common stock issued in PIPE Financing, net of issuance costs | 71,130 | — |
| Net cash provided by financing activities | 135,468 | — |
| Effects of exchange rates on cash and cash equivalents | 652 | 117 |
| Net increase (decrease) in cash and cash equivalents | $91,044 | $(6,707) |
| Cash and cash equivalents, beginning of year | $12,118 | $15,321 |
| Cash and cash equivalents, end of year | $103,162 | $8,731 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for income taxes, net | $14 | $1 |
| Supplemental disclosure of non-cash investing and financing information: | ||
| Accretion of redeemable convertible preferred shares | $7,046 | $8,757 |
| Exchange of preferred shares into common stock upon closing of reverse recapitalization | $185,049 | $— |
| Forgiveness of term loan upon closing of reverse recapitalization | $22,989 | $— |
| Reverse recapitalization issuance costs in accrued expenses | $3,500 | $— |
| Issuance of promissory note in connection with divesture | $6,720 | $— |
| Net assets derecognized in connection with Non-OX40 Divestiture | $5,193 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.